{"id":9530,"date":"2020-12-11T13:54:27","date_gmt":"2020-12-11T13:54:27","guid":{"rendered":"https:\/\/todaysveterinarybusiness.com\/?p=9530"},"modified":"2022-06-15T17:46:44","modified_gmt":"2022-06-15T17:46:44","slug":"kind-030-kindred-elanco-agreement","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/","title":{"rendered":"Elanco Obtains Rights to KindredBio Parvovirus Therapy"},"content":{"rendered":"<p>Kindred Biosciences Inc. could earn tens of millions of dollars as part of an agreement with Elanco Animal Health involving KindredBio\u2019s promising canine parvovirus treatment, KIND-030.<\/p>\n<p>An estimated 250,000 cases of <a href=\"https:\/\/todaysveterinarynurse.com\/articles\/how-and-why-to-feed-canine-parvovirus-patients-right-away\/\">canine parvovirus<\/a> occur annually in the United States, according to Banfield Pet Hospital. Dogs can be vaccinated against the deadly disease, which has no approved cure.<\/p>\n<p>The two companies reported that Elanco was granted exclusive global rights to KIND-030, an monoclonal antibody that could be used as prophylactic therapy to prevent clinical signs of canine parvovirus infection and as a treatment of established parvovirus infection. Positive results from a pivotal efficacy study of the prophylactic indication were announced in September.<\/p>\n<p>\u201cCompletion of the upcoming pivotal efficacy study for the therapeutic indication is expected in the first quarter of 2021,\u201d the company stated. \u201cKindredBio will provide an update on the timing of KIND-030\u2019s expected approval at the time of announcing the company\u2019s fourth-quarter 2020 results.\u201d<\/p>\n<p>Regulatory approval would be a big revenue generator for <a href=\"https:\/\/todaysveterinarybusiness.com\/kindredbio-sells-mirataz-as-part-of-a-restructuring\/\">KindredBio<\/a>.<\/p>\n<p>\u201cUnder the terms of the agreement, KindredBio will receive an upfront payment of $500,000, development milestone payments of up to $16 million upon achievement of certain development, regulatory and manufacturing targets, and sales milestones in an aggregate amount of up to $94 million payable throughout the term of the agreement,\u201d the company stated. \u201cFurthermore, royalty payments are to range from the low to high teens.\u201d<\/p>\n<p>Elanco, which manufactures animal drugs and vaccines and distributes them worldwide, has high hopes for KIND-030.<\/p>\n<p>\u201cWith parvovirus on the rise, it\u2019s more important than ever to bring a new treatment option to veterinarians for this devastating and deadly disease,\u201d said Aaron Schacht, executive vice president of innovation, regulatory and business development. \u201cGiven our significant global access to veterinarians and pet owners, Elanco has a proven track record of partnering with biotech companies, leveraging our R&amp;D capabilities and our skilled team of experts to advance and prove the potential of novel treatments like KIND-030.\u201d<\/p>\n<hr \/>\n<p><em>Did you know a subscription to Today\u2019s Veterinary Business is free to qualified veterinary professionals? All you have to do is <a href=\"https:\/\/todaysveterinarybusiness.com\/subscribe\/\">sign up here<\/a> (and renew each year). You also can sign up to receive the Today\u2019s Veterinary Business weekly e-newsletter.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The monoclonal antibody KIND-030 has shown promise on its path to possible regulatory approval.<\/p>\n","protected":false},"author":45,"featured_media":9532,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-9530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","column-news","clinical_topics-news","clinical_topics-veterinary-products"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.7 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Elanco Obtains Rights to KindredBio Parvovirus Therapy | Today&#039;s Veterinary Business<\/title>\n<meta name=\"description\" content=\"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elanco Obtains Rights to KindredBio Parvovirus Therapy\" \/>\n<meta property=\"og:description\" content=\"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Today&#039;s Veterinary Business\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/todaysveterinarybusiness\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T13:54:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-15T17:46:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"544\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Louise S. Dunn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:site\" content=\"@tvbpublication\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Louise S. Dunn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/\"},\"author\":{\"name\":\"Louise S. Dunn\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\"},\"headline\":\"Elanco Obtains Rights to KindredBio Parvovirus Therapy\",\"datePublished\":\"2020-12-11T13:54:27+00:00\",\"dateModified\":\"2022-06-15T17:46:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/\"},\"wordCount\":374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/12\\\/Parvovirus.jpg\",\"articleSection\":[\"Online\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/\",\"name\":\"Elanco Obtains Rights to KindredBio Parvovirus Therapy | Today&#039;s Veterinary Business\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/12\\\/Parvovirus.jpg\",\"datePublished\":\"2020-12-11T13:54:27+00:00\",\"dateModified\":\"2022-06-15T17:46:44+00:00\",\"description\":\"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/12\\\/Parvovirus.jpg\",\"contentUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2020\\\/12\\\/Parvovirus.jpg\",\"width\":1024,\"height\":544,\"caption\":\"KIND-030 CPV\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/kind-030-kindred-elanco-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elanco Obtains Rights to KindredBio Parvovirus Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#website\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"name\":\"Today&#039;s Veterinary Business\",\"description\":\"Veterinary Business Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#organization\",\"name\":\"Today's Veterinary Business\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"contentUrl\":\"https:\\\/\\\/todaysveterinarybusiness.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/02\\\/tvb-logo.png\",\"width\":258,\"height\":71,\"caption\":\"Today's Veterinary Business\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/todaysveterinarybusiness\",\"https:\\\/\\\/x.com\\\/tvbpublication\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/todaysveterinarybusiness\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarybusiness.com\\\/#\\\/schema\\\/person\\\/06c2358bd95d11022006429d3cfecbeb\",\"name\":\"Louise S. Dunn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g\",\"caption\":\"Louise S. Dunn\"},\"sameAs\":[\"http:\\\/\\\/www.tvb.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Elanco Obtains Rights to KindredBio Parvovirus Therapy | Today&#039;s Veterinary Business","description":"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Elanco Obtains Rights to KindredBio Parvovirus Therapy","og_description":"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.","og_url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/","og_site_name":"Today&#039;s Veterinary Business","article_publisher":"https:\/\/www.facebook.com\/todaysveterinarybusiness","article_published_time":"2020-12-11T13:54:27+00:00","article_modified_time":"2022-06-15T17:46:44+00:00","og_image":[{"width":1024,"height":544,"url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg","type":"image\/jpeg"}],"author":"Louise S. Dunn","twitter_card":"summary_large_image","twitter_creator":"@tvbpublication","twitter_site":"@tvbpublication","twitter_misc":{"Written by":"Louise S. Dunn","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#article","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/"},"author":{"name":"Louise S. Dunn","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb"},"headline":"Elanco Obtains Rights to KindredBio Parvovirus Therapy","datePublished":"2020-12-11T13:54:27+00:00","dateModified":"2022-06-15T17:46:44+00:00","mainEntityOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/"},"wordCount":374,"commentCount":0,"publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg","articleSection":["Online"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/","name":"Elanco Obtains Rights to KindredBio Parvovirus Therapy | Today&#039;s Veterinary Business","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#primaryimage"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg","datePublished":"2020-12-11T13:54:27+00:00","dateModified":"2022-06-15T17:46:44+00:00","description":"Kindred Biosciences could earn tens of millions of dollars in a partnership involving KIND-030, its promising canine parvovirus therapy.","breadcrumb":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#primaryimage","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg","contentUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2020\/12\/Parvovirus.jpg","width":1024,"height":544,"caption":"KIND-030 CPV"},{"@type":"BreadcrumbList","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/kind-030-kindred-elanco-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/"},{"@type":"ListItem","position":2,"name":"Elanco Obtains Rights to KindredBio Parvovirus Therapy"}]},{"@type":"WebSite","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#website","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","name":"Today&#039;s Veterinary Business","description":"Veterinary Business Magazine","publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#organization","name":"Today's Veterinary Business","url":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/","url":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","contentUrl":"https:\/\/todaysveterinarybusiness.com\/wp-content\/uploads\/sites\/2\/2022\/02\/tvb-logo.png","width":258,"height":71,"caption":"Today's Veterinary Business"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/todaysveterinarybusiness","https:\/\/x.com\/tvbpublication","https:\/\/www.linkedin.com\/company\/todaysveterinarybusiness"]},{"@type":"Person","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/#\/schema\/person\/06c2358bd95d11022006429d3cfecbeb","name":"Louise S. Dunn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/279afec084b15ccaa49dd347b051da6bd5240661c20b0dd5410687e84182ede5?s=96&d=mm&r=g","caption":"Louise S. Dunn"},"sameAs":["http:\/\/www.tvb.com"]}]}},"_links":{"self":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/comments?post=9530"}],"version-history":[{"count":2,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9530\/revisions"}],"predecessor-version":[{"id":18694,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/posts\/9530\/revisions\/18694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media\/9532"}],"wp:attachment":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/media?parent=9530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/categories?post=9530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/wp-json\/wp\/v2\/tags?post=9530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}